V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Atea Pharmaceuticals Executive Compensation (FY25)

AVIR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jean-Pierre Sommadossi
Latest say-on-pay support
=
June 18, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Atea Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 22, 2026
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Atea Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
330 figures on this page: 326 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jean-Pierre Sommadossi: $4,202,323 → $3,403,752 (19.0% lower)
Say-on-pay support: 79.3% → 94.1% (14.8 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Atea Pharmaceuticals' chief executive and what were they paid?
Jean-Pierre Sommadossi, President, Chief Executive Officer and Chairman of the Board, received $3,403,752 in total compensation for fiscal 2025. Sommadossi's total moved 19.0% lower from the $4,202,323 reported for fiscal 2024.
What was Atea Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Atea Pharmaceuticals' peer group?
Companies named in the disclosed peer group include 89bio, Inc., Alector, Inc., Allakos Inc., AlloVir, Inc. and Anaptys Bio, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer,
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
John Vavricka
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
John Vavricka
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
John Vavricka
Chief Commercial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board
◇—◇◇◇——◇
Janet Hammond
Chief Development Officer
◇—◇◇◇—◇◇
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal
◇—◇◇◇—◇◇
Maria Arantxa Horga
Chief Medical Officer
◇—◇◇◇—◇◇
John Vavricka
Chief Commercial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrea CorcoranOPTION◇——◇—◇◇
Andrea CorcoranPSU◇◇◇—◇—◇
Janet HammondPSU◇◇◇—◇—◇
Janet HammondOPTION◇——◇—◇◇
Jean-Pierre SommadossiPSU◇◇◇—◇—◇
Jean-Pierre SommadossiOPTION◇——◇—◇◇
John VavrickaOPTION◇——◇—◇◇
John VavrickaPSU◇◇◇—◇—◇
Maria Arantxa HorgaPSU◇◇◇—◇—◇
Maria Arantxa HorgaOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrea CorcoranPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇1/30/2035
Option◇—◇1/30/2034
Option◇—◇1/30/2033
Option◇—◇1/30/2032
John VavrickaRSU◇◇——
PSU◇◇——
Option◇—◇1/30/2023
Option◇—◇1/30/2024
PSU◇◇——
RSU◇◇——
Option◇—◇1/30/2035
Option◇—◇1/30/2032
Janet HammondOption◇—◇1/30/2035
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/30/2034
Option◇—◇1/30/2033
Option◇—◇1/30/2032
Jean-Pierre SommadossiPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/30/2034
Option◇—◇1/30/2033
Option◇—◇1/30/2032
Maria Arantxa HorgaPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/30/2034
Option◇—◇1/30/2035
Option◇—◇1/30/2033
Option◇—◇1/30/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Janet Hammond
Chief Development Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Jean-Pierre Sommadossi
President, Chief Executive Officer and Chairman of the Board · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
John Vavricka
Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Maria Arantxa Horga
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arthur Kirsch
◇—◇———◇
Howard Berman
◇—◇———◇
Jerome Adams
◇◇◇——◇◇
Franklin Berger
◇◇◇———◇
Barbara Duncan
◇◇◇———◇
Polly Murphy
◇◇◇———◇
Bruno Lucidi
◇◇◇———◇
Bruce Polsky
◇◇◇———◇
Jean-Pierre Sommadossi served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 89bio, Inc. ETNB
  • Alector, Inc. ALEC
  • Allakos Inc. ALLK
  • AlloVir, Inc. ALVR
  • Anaptys Bio, Inc. ANAB
  • Annexion, Inc. symbol not shown
  • Arbutus Biopharma Corporation ABUS
  • Arcturus Therapeutics Holdings, Inc. ARCT
  • Assembly Biosciences, Inc. ASMB
  • Chimerix, Inc. CMRX
  • Enanta Pharmaceuticals, Inc. ENTA
  • Gossamer Bio, Inc. GOSS
  • Inozyme Pharma, Inc. INZY
  • Invivyd, Inc. IVVD
  • Kodiak Sciences Inc. KOD
  • Replimune Group, Inc. REPL
  • Scholar Rock Holding Corporation SRRK
  • Vir Biotechnology, Inc. VIR
  • Y-mABs Therapeutics, Inc. YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 18, 2026=◇◇◇
2024June 20, 2025=◇◇◇
2023June 21, 2024=◇◇◇
2021June 16, 2022=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jean-Pierre Sommadossi (President, Chief Executive Officer and Chairman of the Board), FY2025 total compensation $3,403,752 (base salary $703,490) [exec_comp, SEC accession 0001193125-26-182293, filed 2026-04-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Atea Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Atea Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Atea Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Atea Pharmaceuticals' disclosed peer group is defensible, who names Atea Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
330 figures on this page: 326 cited to the filing that reported them, 4 calculated from figures it prints.
326 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-26-277639
  2. 0001193125-26-182293
    Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards · NAMED EXECUTIVE OFFICER COMPENSATION
  3. 0001193125-25-143750
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-24-165886
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001193125-23-171257
  6. 0000950170-23-015773
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Atea Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AVIR (accessed 2026).
Short form: data: Velarion

The Atea Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Atea Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Atea Pharmaceuticals discloses

The companies named in AVIR's own disclosed peer group.

89bio, Inc.Alector, Inc.Allakos Inc.Anaptys Bio, Inc.Arbutus Biopharma CorporationArcturus Therapeutics Holdings, Inc.Assembly Biosciences, Inc.Chimerix, Inc.Enanta Pharmaceuticals, Inc.Gossamer Bio, Inc.Inozyme Pharma, Inc.Invivyd, Inc.Kodiak Sciences Inc.Replimune Group, Inc.Scholar Rock Holding CorporationVir Biotechnology, Inc.Y-mABs Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy